Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREON for EPI from causes other than CF, CP, Pancreatectomy, or Cancer
NCT04315311Phase 4Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- May 2020
- Primary completion
- Sep 2021
- Modality
- Replacement Enzymes
01
Overview
A Phase 4 trial of pancrelipase in exocrine pancreatic insufficiency (EPI), sponsored by AbbVie Inc.. Planned start May 2020; status: withdrawn.
02
Drugs
pancrelipase
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT04315311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315311.